UNSPSC 51434930: Eprosartan/hydrochlorothiazide

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434930 Eprosartan/hydrochlorothiazide is a Commodity code that covers branded and generic antihypertensive combination medications, though recent state and local solicitation activity under this code shows limited direct demand for the specific drug combination. Instead, state and local health systems and emergency services are soliciting broader pharmaceutical procurement across multiple therapeutic classes — including advanced life support medications, generic multi-source drugs, and prescription benefit management infrastructure. The issuing bodies span city fire rescue departments, state health and human services agencies, and multistate cooperative purchasing alliances. State and local governments buy pharmaceuticals through direct purchase agreements with manufacturers and authorized wholesalers, cooperative purchasing vehicles that aggregate demand across multiple jurisdictions, and prescription benefit programs that negotiate pricing and supply chain relationships with manufacturers and pharmacy benefit managers.

Activity appears concentrated in Texas and Minnesota, with the Texas Health and Human Services Commission exploring direct-to-manufacturer prescription programs and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) administering a two-year RFP for generic multi-source pharmaceuticals across participating state and local facilities in Minnesota and Oregon, due March 26, 2026. The City of Tampa's Purchasing Department posted an IFB for Advanced Life Support Medications (Solicitation 26P00188, due April 8, 2026) valued at $40,000, requiring supply of Labetalol, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with a one-year contract term and renewal options. The MMCAP RFP specifies fixed pricing weighted at 10 percent and price competitiveness at 75 percent of evaluation criteria, with awarded vendors required to maintain relationships with three authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson), comply with cGMP and Drug Supply Chain Security Act requirements, and pay a 3 percent administrative fee on all purchases. No recent solicitations target eprosartan/hydrochlorothiazide specifically; procurement activity under this code would fall within broader pharmaceutical supply agreements rather than standalone medication line-item bids.